4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Fulcrum Therapeutics, Inc. (FULC) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 55 employees. Its market capitalization is roughly $237 million. In the fiscal year ended 2025-12-31, FULC reported $0M in revenue and ($75M) in net income.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $80M | $3M | $6M |
| Operating Income (EBIT) | ($85M) | ($20M) | ($111M) | ($112M) |
| Net Income | ($75M) | ($10M) | ($97M) | ($110M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($22M) | ($23M) | ($22M) | ($20M) | ($20M) | — |
| Net Income | ($19M) | ($20M) | ($20M) | ($17M) | ($18M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $366M | $261M | $258M | $227M | — |
| Total Liabilities | $17M | $18M | $22M | $28M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive FULC viewer.
About TickerBase · Data methodology & sources